Evercore ISI Group Maintains Outperform on BridgeBio Pharma, Raises Price Target to $130

Benzinga Newsdesk www.benzinga.com Positive 92.4%

Neg 0% Neu 0% Pos 92.4%

Evercore ISI Group analyst Cory Kasimov maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and raises the price target from $125 to $130.